Bridgebio Pharma Inc. (bbio 2.25 02/01/29)
13F holders, Q4 2025 (December 31)5holders +1
1new positions
0sold out
$1.13avg. 13F price*
At the end of Q4 2025, 5 institutions reported holding Bridgebio Pharma Inc. (bbio 2.25 02/01/29) in their 13F filings, up 1 from Q3 2025. 1 opened new positions and 0 sold out. The largest holders were Polar Capital Holdings Plc ($27.0M), BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($2.8M) and New York State Common Retirement Fund ($1.5M).
- Company
- Bridgebio Pharma Inc. (bbio 2.25 02/01/29)
- CUSIP
- 10806XAD4
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $27.0M |
| Exits | 0 | $0 |
All 13F filers, Q3 2025 → Q4 2025: 24,090,000 shares bought and 1,516,000 shares sold, net +22,574,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Polar Capital Holdings Plc | 0.12% | New | 24,000,000 | $27.0M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.00% | No change | 2,500,000 | $2.8M |
| New York State Common Retirement Fund | 0.00% | Reduce -53.0% | 1,343,000 | $1.5M |
| Sei Investments Co. | 0.00% | Add +33.2% | 361,000 | $405K |
| Bank of New York Mellon Corp | 0.00% | No change | 200,000 | $225K |
"% of holder's portfolio" is BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29)'s weight in each manager's 13F, not the share of Bridgebio Pharma Inc. (bbio 2.25 02/01/29) the manager owns.